[go: up one dir, main page]

DZ3030A1 - Procédé et produits intermédiaires pour la préparation de composés anti-cancéreux. - Google Patents

Procédé et produits intermédiaires pour la préparation de composés anti-cancéreux.

Info

Publication number
DZ3030A1
DZ3030A1 DZ000059A DZ000059A DZ3030A1 DZ 3030 A1 DZ3030 A1 DZ 3030A1 DZ 000059 A DZ000059 A DZ 000059A DZ 000059 A DZ000059 A DZ 000059A DZ 3030 A1 DZ3030 A1 DZ 3030A1
Authority
DZ
Algeria
Prior art keywords
preparation
intermediate products
cancer compounds
cancer
compounds
Prior art date
Application number
DZ000059A
Other languages
English (en)
French (fr)
Inventor
Richard Shelton Lehner
Timothy Norris
Dinos Paul Santafianos
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DZ3030A1 publication Critical patent/DZ3030A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
    • C22B15/00—Obtaining copper
    • C22B15/0002—Preliminary treatment
    • C22B15/0004—Preliminary treatment without modification of the copper constituent
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
    • C22B15/00—Obtaining copper
    • C22B15/0063—Hydrometallurgy
    • C22B15/0065—Leaching or slurrying
    • C22B15/0067—Leaching or slurrying with acids or salts thereof
    • C22B15/0071—Leaching or slurrying with acids or salts thereof containing sulfur
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P10/00—Technologies related to metal processing
    • Y02P10/20—Recycling

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Mechanical Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Metallurgy (AREA)
  • Materials Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DZ000059A 1999-03-31 2000-03-29 Procédé et produits intermédiaires pour la préparation de composés anti-cancéreux. DZ3030A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12707299P 1999-03-31 1999-03-31

Publications (1)

Publication Number Publication Date
DZ3030A1 true DZ3030A1 (fr) 2004-03-27

Family

ID=22428179

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ000059A DZ3030A1 (fr) 1999-03-31 2000-03-29 Procédé et produits intermédiaires pour la préparation de composés anti-cancéreux.

Country Status (49)

Country Link
US (1) US6476040B1 (xx)
EP (1) EP1044969B1 (xx)
JP (2) JP3420549B2 (xx)
KR (2) KR100430210B1 (xx)
CN (2) CN100351242C (xx)
AP (2) AP1655A (xx)
AR (1) AR018705A1 (xx)
AT (1) ATE348098T1 (xx)
AU (2) AU781402B2 (xx)
BG (1) BG65194B1 (xx)
BR (1) BRPI0001486B8 (xx)
CA (2) CA2427221C (xx)
CO (1) CO5160273A1 (xx)
CR (1) CR6165A (xx)
CZ (1) CZ299426B6 (xx)
DE (1) DE60032275T2 (xx)
DK (1) DK1044969T3 (xx)
DZ (1) DZ3030A1 (xx)
EA (3) EA005892B1 (xx)
EE (1) EE04589B1 (xx)
EG (1) EG22506A (xx)
ES (1) ES2278578T3 (xx)
GE (1) GEP20022653B (xx)
GT (1) GT200000037A (xx)
HR (1) HRP20000182B1 (xx)
HU (1) HU227698B1 (xx)
ID (1) ID25427A (xx)
IL (2) IL135245A0 (xx)
IS (1) IS2468B (xx)
MA (1) MA25087A1 (xx)
MY (1) MY136270A (xx)
NO (2) NO321952B1 (xx)
NZ (2) NZ512818A (xx)
OA (1) OA11335A (xx)
PA (1) PA8491901A1 (xx)
PE (1) PE20001599A1 (xx)
PL (1) PL339330A1 (xx)
PT (1) PT1044969E (xx)
RS (1) RS49836B (xx)
SG (2) SG115536A1 (xx)
SK (1) SK287339B6 (xx)
SV (1) SV2002000047A (xx)
TN (1) TNSN00064A1 (xx)
TR (1) TR200000837A2 (xx)
TW (1) TW553939B (xx)
UA (2) UA80955C2 (xx)
UY (1) UY26086A1 (xx)
YU (1) YU13200A (xx)
ZA (1) ZA200001586B (xx)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
HU230302B1 (hu) 2000-10-20 2015-12-28 Eisai R&D Management Co., Ltd. Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények
EP1408980A4 (en) 2001-06-21 2004-10-20 Ariad Pharma Inc NEW QUINAZOLINES AND THEIR USE
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
WO2004006846A2 (en) 2002-07-15 2004-01-22 Exelixis, Inc. Receptor-type kinase modulators and methods of use
US7148231B2 (en) * 2003-02-17 2006-12-12 Hoffmann-La Roche Inc. [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
ATE508747T1 (de) 2003-03-10 2011-05-15 Eisai R&D Man Co Ltd C-kit kinase-hemmer
US8309562B2 (en) * 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
CN1984660B (zh) 2003-07-03 2010-12-15 美瑞德生物工程公司 作为天冬氨酸特异性半胱氨酸蛋白酶活化剂和细胞程序死亡诱导剂的4-芳基氨基-喹唑啉
WO2006074147A2 (en) 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
ATE395346T1 (de) 2003-09-16 2008-05-15 Astrazeneca Ab Chinazolinderivate als tyrosinkinaseinhibitoren
CA2744997A1 (en) 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and method of use
CN100450998C (zh) 2003-11-11 2009-01-14 卫材R&D管理有限公司 脲衍生物的制备方法
SI1746999T1 (sl) * 2004-05-06 2012-01-31 Warner Lambert Co 4-fenilamino-kinazolin-6-il-amidi
EP1797881B1 (en) 2004-09-17 2009-04-15 Eisai R&D Management Co., Ltd. Medicinal composition with improved stability and reduced gelation properties
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
US7625911B2 (en) * 2005-01-12 2009-12-01 Mai De Ltd. Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion
SI1859793T1 (sl) * 2005-02-28 2011-08-31 Eisai R&D Man Co Ltd Nova kombinirana uporaba sulfonamidne spojine za zdravljenje raka
JP5066446B2 (ja) * 2005-08-01 2012-11-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を予測する方法
EP2281901B1 (en) 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Anti-tumour pharmaceutical composition with angiogenesis inhibitors
CN101316590B (zh) 2005-11-07 2011-08-03 卫材R&D管理有限公司 血管生成抑制剂和c-kit激酶抑制剂的组合使用
WO2007061127A1 (ja) * 2005-11-22 2007-05-31 Eisai R & D Management Co., Ltd. 多発性骨髄腫に対する抗腫瘍剤
EP2036557B1 (en) * 2006-05-18 2015-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for thyroid cancer
US20090203693A1 (en) * 2006-06-29 2009-08-13 Eisai R & D Management Co., Ltd. Therapeutic agent for liver fibrosis
WO2008012105A1 (en) 2006-07-28 2008-01-31 Synthon B.V. Crystalline erlotinib
CN101511793B (zh) 2006-08-28 2011-08-03 卫材R&D管理有限公司 针对未分化型胃癌的抗肿瘤剂
US8372856B2 (en) 2006-10-27 2013-02-12 Synthon Bv Hydrates of erlotinib hydrochloride
US20100048503A1 (en) 2007-01-19 2010-02-25 Eisai R & D Management Co., Ltd. Composition for treatment of pancreatic cancer
AU2008211952B2 (en) 2007-01-29 2012-07-19 Eisai R & D Management Co., Ltd. Composition for treatment of undifferentiated-type of gastric cancer
US8349855B2 (en) * 2007-02-21 2013-01-08 Natco Pharma Limited Polymorphs of erlotinib hydrochloride and method of preparation
JP5524041B2 (ja) 2007-04-04 2014-06-18 シプラ・リミテッド エルロチニブおよびその薬学的に許容可能な塩の製造方法
WO2009002538A2 (en) * 2007-06-25 2008-12-31 Plus Chemicals S.A. Amorphous erlotinib, processes for the preparation thereof, and processes to prepare additional forms of erlotinib
WO2009007984A2 (en) 2007-07-11 2009-01-15 Hetero Drugs Limited An improved process for erlotinib hydrochloride
MX2010002081A (es) * 2007-08-23 2010-06-01 Plus Chemicals Sa Procesos para la preparacion de formas a, b cristalinas y de la forma a cristalina pura de erlotinib hc1.
US20090124642A1 (en) * 2007-08-23 2009-05-14 Augusto Canavesi Crystalline forms of Erlotinib HCI and formulations thereof
US20090076042A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched erlotinib
JP5638244B2 (ja) 2007-11-09 2014-12-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質と抗腫瘍性白金錯体との併用
BRPI0906576A2 (pt) * 2008-01-29 2015-07-07 Eisai R&D Man Co Ltd Composição farmacêutica, kit, uso de um composto, e, agente terapêutico para câncer
CN102083801A (zh) * 2008-03-28 2011-06-01 康瑟特制药公司 喹唑啉衍生物和治疗方法
CA2730226A1 (en) * 2008-07-07 2010-01-14 Plus Chemicals Sa Crystalline forms of erlotinib base and erlotinib hcl
KR101132937B1 (ko) 2008-10-01 2012-04-06 주식회사종근당 Ｎ-(3-에티닐페닐)-6,7-비스(2-메톡시에톡시)-4-퀴나졸린아민 납실레이트 염
WO2010040212A1 (en) * 2008-10-08 2010-04-15 Apotex Pharmachem Inc. Processes for the preparation of erlotinib hydrochloride
KR101733773B1 (ko) 2009-01-16 2017-05-10 엑셀리시스, 인코포레이티드 Ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
WO2010109443A1 (en) 2009-03-26 2010-09-30 Ranbaxy Laboratories Limited Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
WO2011058525A2 (en) 2009-11-12 2011-05-19 Ranbaxy Laboratories Limited Processes for the preparation of erlotinib hydrochloride form a and erlotinib hydrochloride form b
WO2011068404A2 (en) 2009-12-02 2011-06-09 Ultimorphix Technologies B.V. Administration of n-(3-ethynylphenylamino)-6,7-bis(2- methoxyethoxy)-4-quinazolinamine mesylate salt by inhalation
MX2012014776A (es) 2010-06-25 2013-01-29 Eisai R&D Man Co Ltd Agente antitumoral que emplea compuestos con efecto inhibidor de cinasas combinados.
NZ628796A (en) 2010-07-23 2016-02-26 Generics Uk Ltd Pure erlotinib
IT1402029B1 (it) 2010-10-14 2013-08-28 Italiana Sint Spa Procedimento per la preparazione di erlotinib
MX2013009931A (es) 2011-04-18 2013-10-01 Eisai R&D Man Co Ltd Agentes terapeuticos contra tumores.
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CN102267952B (zh) * 2011-06-21 2013-12-11 天津市汉康医药生物技术有限公司 喹唑啉类化合物、其制备方法和用途
CN103420924B (zh) * 2012-05-25 2016-08-31 浙江九洲药业股份有限公司 一种盐酸埃罗替尼晶型a的制备方法
NZ630289A (en) 2012-09-04 2016-08-26 Shilpa Medicare Ltd Crystalline erlotinib hydrochloride process
US9334239B2 (en) 2012-12-21 2016-05-10 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
WO2014118737A1 (en) 2013-01-31 2014-08-07 Ranbaxy Laboratories Limited Erlotinib salts
US10517861B2 (en) 2013-05-14 2019-12-31 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN103333124B (zh) * 2013-05-28 2015-03-25 埃斯特维华义制药有限公司 一种制备盐酸厄洛替尼晶型f的方法
CN106660964B (zh) 2014-08-28 2021-09-03 卫材R&D管理有限公司 高纯度喹啉衍生物及其生产方法
CA2908441A1 (en) 2014-10-28 2016-04-28 Cerbios-Pharma Sa Process for the preparation of erlotinib
PL3263106T3 (pl) 2015-02-25 2024-04-02 Eisai R&D Management Co., Ltd. Sposób tłumienia goryczy pochodnej chinoliny
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
ES2886107T3 (es) 2015-06-16 2021-12-16 Prism Biolab Co Ltd Antineoplásico
AU2016309356B2 (en) 2015-08-20 2021-06-24 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
CN105884653A (zh) * 2016-06-08 2016-08-24 浙江汇能生物股份有限公司 一种埃罗替尼衍生物及其制备方法
CN106279585A (zh) * 2016-08-26 2017-01-04 宁波圣达精工智能科技有限公司 一种阻燃智能密集书架的制备方法
MX380144B (es) 2017-02-08 2025-03-12 Eisai R&D Man Co Ltd Composicion farmaceutica de tratamiento de tumores.
CA3061888A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4747498A (en) * 1986-06-27 1988-05-31 Sunbeam Plastics Corporation Safety dispensing closure-container package
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
JP2657760B2 (ja) * 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
ATE205483T1 (de) * 1995-03-30 2001-09-15 Pfizer Chinazolinderivate
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
DE69709319T2 (de) 1996-03-05 2002-08-14 Astrazeneca Ab, Soedertaelje 4-anilinochinazolin derivate
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6225499B1 (en) 1997-07-14 2001-05-01 Catalytica Pharmaceuticals, Inc. Process for preparing aminoarylacetylenes
CN101219999A (zh) 1998-04-29 2008-07-16 Osi药物公司 N-(乙炔苯基)-6,7-双(2-甲氧基乙氧基)-4-喹唑啉胺甲磺酸盐无水物和一水合物

Also Published As

Publication number Publication date
TR200000837A2 (tr) 2000-11-21
KR100430210B1 (ko) 2004-05-03
MY136270A (en) 2008-09-30
ZA200001586B (en) 2001-10-01
PL339330A1 (en) 2000-10-09
OA11335A (en) 2003-12-10
AU2005201494B2 (en) 2008-02-07
RS49836B (sr) 2008-08-07
HRP20000182A2 (en) 2001-04-30
GEP20022653B (en) 2002-03-25
CA2302965C (en) 2004-02-17
CZ299426B6 (cs) 2008-07-23
PT1044969E (pt) 2007-05-31
DE60032275T2 (de) 2007-07-12
UY26086A1 (es) 2000-10-31
AP1265A (en) 2004-03-26
HRP20000182B1 (en) 2007-10-31
IL168036A (en) 2006-12-10
NZ512818A (en) 2003-01-31
EA200000274A2 (ru) 2000-10-30
KR20010014658A (ko) 2001-02-26
MA25087A1 (fr) 2000-10-01
ID25427A (id) 2000-10-05
HUP0001353A3 (en) 2002-01-28
HU227698B1 (en) 2011-12-28
EA005561B1 (ru) 2005-04-28
TNSN00064A1 (fr) 2005-11-10
HU0001353D0 (en) 2000-06-28
IS2468B (is) 2008-12-15
EE04589B1 (et) 2006-02-15
UA70928C2 (uk) 2004-11-15
CN1276370A (zh) 2000-12-13
CN100351242C (zh) 2007-11-28
DK1044969T3 (da) 2007-04-23
CZ20001155A3 (cs) 2001-03-14
AU781402B2 (en) 2005-05-19
ATE348098T1 (de) 2007-01-15
BRPI0001486B1 (pt) 2019-01-29
NO20001648L (no) 2000-10-02
CA2427221C (en) 2008-09-16
US6476040B1 (en) 2002-11-05
JP2003176274A (ja) 2003-06-24
CN1699350A (zh) 2005-11-23
EG22506A (en) 2003-03-31
EP1044969A2 (en) 2000-10-18
CR6165A (es) 2008-10-10
UA80955C2 (en) 2007-11-26
AU2005201494A1 (en) 2005-05-05
NO324745B1 (no) 2007-12-03
AR018705A1 (es) 2001-11-28
BRPI0001486B8 (pt) 2021-05-25
BG104278A (en) 2001-08-31
EA200201245A1 (ru) 2003-04-24
KR100430209B1 (ko) 2004-05-03
SK287339B6 (sk) 2010-07-07
SV2002000047A (es) 2002-01-23
NO20001648D0 (no) 2000-03-30
EA004654B1 (ru) 2004-06-24
ES2278578T3 (es) 2007-08-16
EA200000274A3 (ru) 2003-02-27
EP1044969B1 (en) 2006-12-13
IL135245A0 (en) 2001-05-20
GT200000037A (es) 2001-09-21
SG115536A1 (en) 2005-10-28
HUP0001353A2 (hu) 2001-05-28
CN1215061C (zh) 2005-08-17
CO5160273A1 (es) 2002-05-30
SG121687A1 (en) 2006-05-26
EP1044969A3 (en) 2000-11-29
PE20001599A1 (es) 2001-01-18
HK1029790A1 (en) 2001-04-12
DE60032275D1 (de) 2007-01-25
PA8491901A1 (es) 2001-12-14
JP2000290262A (ja) 2000-10-17
NO321952B1 (no) 2006-07-24
EA200201244A1 (ru) 2003-04-24
AP2000001778A0 (en) 2000-03-31
AU2262000A (en) 2000-10-05
CA2302965A1 (en) 2000-09-30
AP1655A (en) 2006-09-01
JP4074509B2 (ja) 2008-04-09
IS5411A (is) 2000-10-02
KR20020084903A (ko) 2002-11-13
EA005892B1 (ru) 2005-06-30
JP3420549B2 (ja) 2003-06-23
EE200000255A (et) 2000-12-15
TW553939B (en) 2003-09-21
NZ503683A (en) 2001-09-28
BG65194B1 (bg) 2007-06-29
CA2427221A1 (en) 2000-09-30
SK4442000A3 (en) 2000-10-09
NO20054715L (no) 2000-10-02
YU13200A (sh) 2002-10-18
BR0001486A (pt) 2001-05-02

Similar Documents

Publication Publication Date Title
DZ3030A1 (fr) Procédé et produits intermédiaires pour la préparation de composés anti-cancéreux.
DZ3079A1 (fr) Procédé pour la préparation de 4-carboxy-amino-2-substitué-1,2,3,4 tétrahydroquinolé.
MA23528A1 (fr) Procede de preparation de produits pharmaceutiques
EP0661325A3 (en) Process for the continuous production of lactide copolymer.
MA22889A1 (fr) Procede de preparation de produits nouveaux
DZ2963A1 (fr) Dérivés de bicycliques substituées nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ712A1 (fr) Nouveaux dérivés de 2-2 iminobisethanol utiles comme médecaments, intermédiaires pour leur préparation et procédés pour la préparation de ces dérivés et intermédiaires.
EP0659797A3 (en) Process for the production of polyesters.
DZ2890A1 (fr) 4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA24885A1 (fr) PROCéDé PERFECTIONNé POUR LA PRéPARATION DE BASES DE SCHIFF ET PRODUITS AINSI OBTENUS
HUP9700126A3 (en) 2-oxo- and 2-thio-1,2-dihydroquinolinyl-oxazotidinone derivatives and pharmaceutical compositions containing them, process for producing the compounds and intermediates of them
DZ3045A1 (fr) Dérivés de i 3-méthyl-érythromycine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ1872A1 (fr) Procédé de préparation de produits pharmaceutiques.
MA23118A1 (fr) Procede pour la preparation de compositions de vaccins contre la grippe .
DZ2712A1 (fr) Composition de mésylate de trovafloxacine et procédé pour sa préparation.
DZ2912A1 (fr) Procédé pour la préparation de pyrazolo Ä4,3-DÜpyrimidine-7-ones, et intermédiaires pour ce procédé.
FR2715402B1 (fr) Nouvelles phénylimidazolines éventuellement substituées, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
EP0752405A3 (en) Process for the production of phenol
FR2682088B1 (fr) Conditionnement pour la preparation extemporanee de produits medicamenteux.
DZ1946A1 (fr) Procédé pour la préparation de supports.
EP0645369A3 (en) Process for the preparation of enzyme derivatives.
EP0669363A3 (en) Process for the preparation of polyorganosilane.
DZ2430A1 (fr) Procédé pour la préparation de dérivés de thiazolidinedione substitués.
DZ3083A1 (fr) Composés nouveaux inhibiteurs de protéases, procédé pour leur préparation et compositions pharmaceutiques les conentant.
DZ2677A1 (fr) Compositions nouvelles renfermant des dérivés de benzopyranne et pyridopyranne et procédé pour leur préparation.